.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The recent study by Mayo AK et al. evaluates Obeticholic Acid liver safety in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Although the FDA approved Obeticholic acid (OCA) for primary biliary cholangitis in 2016, they recently rejected it for the treatment of MASLD. This regulatory decision stemmed from significant liver safety concerns that emerged during clinical trials. To understand these risks, researchers employed the DILIsym model to simulate OCA's toxicological profile in virtual patient populations.
The research team utilized physiologically based pharmacokinetic (PBPK) modeling to estimate drug exposures in the liver, gut, and plasma. Interestingly, virtual MASLD patients showed significantly higher exposures compared to healthy individuals. Furthermore, the model integrated critical mechanisms such as bile acid transporter inhibition and mitochondrial dysfunction. These specific factors directly contribute to elevations in liver biomarkers, including alanine aminotransferase (ALT) and aspartate aminotransferase (AST).
The DILIsym simulations accurately mirrored the liver injury patterns observed in real-world clinical subjects. Specifically, the model showed that bile acid transporter inhibition alone could trigger biomarker elevations similar to those seen in clinical trials. In contrast, mitochondrial uncoupling only caused significant damage at extremely high doses. Therefore, the study confirms that predictive modeling can effectively identify hepatotoxicity risks before late-stage clinical failures occur.
In conclusion, these findings explain the regulatory hurdles that led to the withdrawal of OCA from the US market for MASLD. For the medical community, this research highlights the necessity of precise dosing and rigorous safety monitoring in steatotic liver disease. Moving forward, Quantitative Systems Toxicology (QST) models will likely play a vital role in drug development for complex metabolic conditions. Consequently, these tools help ensure that only the safest therapies reach the bedside.
The FDA rejected Obeticholic Acid for MASLD treatment primarily due to liver safety concerns. Clinical trials revealed significant elevations in liver biomarkers and an increased risk of drug-induced liver injury in this specific patient population.
DILIsym is a Quantitative Systems Toxicology model. It integrates pharmacokinetic data with mechanistic pathways, such as bile acid transport and mitochondrial function, to simulate how a drug affects liver health in different populations.
The primary mechanism identified is the inhibition of bile acid transporters. This causes a toxic accumulation of bile acids within the liver. At very high doses, mitochondrial dysfunction also contributes to the injury.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship. Refer to the latest local and national guidelines for clinical practice.
References
Mayo AK et al. Quantitative Systems Toxicology Model Predicts Obeticholic Acid-Associated Liver Injury in Metabolic Dysfunction-Associated Steatotic Liver Disease. Clin Pharmacol Ther. 2026 Jun 22. doi: 10.1002/cpt.70355. PMID: 42332345.
Younossi ZM, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019;394(10215):2184-2196.
U.S. Food and Drug Administration. FDA Integrated Review: Obeticholic Acid for Treatment of Pre-cirrhotic NASH with Liver Fibrosis. 2023.
"
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A new in silico study using the DILIsym model reveals why Obeticholic Acid (OCA) faced liver safety hurdles in MASLD trials. The research highlights bile acid transporter inhibition as a key driver of hepatotoxicity, validating the FDA's cautious approach to OCA approval in metabolic liver diseases.
4 weeks back
Researchers at Kyushu University have uncovered a novel compound, lipoic acid trisulfide (LASSS), that enhances hepatocyte growth factor (HGF) signaling and protects against nitration-induced protein dysfunction, presenting a potential breakthrough for age-related muscle atrophy and sarcopenia.
Yesterday
A study identifies a critical hypospadias gene-environment interaction. Research shows that the risk gene DNAH8 and DEHP exposure combine to disrupt steroidogenesis and mesenchymal progenitor cell differentiation, significantly increasing the risk of severe urethral malformations in male fetuses.
5 days back
A pre-clinical study reveals that elevated serum pro-N-cadherin levels correlate strongly with severe cardiac fibrosis and diastolic dysfunction following radiation exposure, promising a potential early biomarker for radiation-related heart disease.
3 days back
Discover how biophysical forces shape tissue formation and regeneration. This review explores mechanotransduction in tissue development, from molecular sensors like integrins to tissue-scale flows, highlighting critical implications for regenerative medicine and functional organoid engineering.
Last week
A groundbreaking study utilizes single-cell RNA sequencing to map the tumor microenvironment of ovarian steroid cell tumors-not otherwise specified (SCT-NOS), identifying key steroidogenic subtypes and immune cell distributions that drive hyperandrogenism and tumor progression.
Last week
